Overview
FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)
Status:
Completed
Completed
Trial end date:
2010-07-01
2010-07-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of FOSAMAX PLUS / FOSAMAX PLUS D through collecting the safety information according to the Re-examination Regulation for New Drugs. Note: FOSAMAX PLUS D is known as FOSAMAX PLUS in several markets. FOSAMAX PLUS (70 mg/2800 IU) and FOSAMAX PLUS D (70 mg/5600 IU).Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Merck Sharp & Dohme Corp.Treatments:
Alendronate
Criteria
Inclusion Criteria:- Participants who are treated with FOSAMAX PLUS / FOSAMAX PLUS D within label for the
first time
Exclusion Criteria:
- Participants who have a contraindication to FOSAMAX PLUS / FOSAMAX PLUS D according to
the current local label